tiprankstipranks
LakeShore Biopharma (LSB)
NASDAQ:LSB
US Market

LakeShore Biopharma (LSB) Income Statement

64 Followers

LakeShore Biopharma Income Statement

Last quarter (Q ), LakeShore Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q, LakeShore Biopharma's net income was $―. See LakeShore Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 23Mar 22Dec 21Dec 20
Total Revenue
-$ 100.00M$ 502.95M$ 0.00$ 0.00
Cost of Revenue
-$ 22.32M$ 117.07M--
Gross Profit
-$ 77.69M$ 385.88M--
Operating Expense
$ 644.37K$ 97.97M$ 481.82M$ 549.18K$ 3.64K
Operating Income
$ -644.37K$ 2.03M$ -95.94M$ -549.18K$ -3.64K
Net Non Operating Interest Income Expense
$ 290.22K$ -4.49M$ -2.72M$ 7.28K$ 0.00
Other Income Expense
$ 9.20M$ -3.79M$ -2.41M$ -3.82K-
Pretax Income
$ 8.85M$ -21.01M$ -101.07M$ -545.73K$ -3.64K
Tax Provision
-$ 164.95K$ 4.94M--
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ 8.85M$ -41.25M$ -236.67M$ -545.73K$ -3.64K
Basic EPS
$ 0.58$ -0.23$ -2.57$ -0.09$ >-0.01
Diluted EPS
$ 0.34$ -1.56$ -2.57$ -0.09$ >-0.01
Basic Average Shares
$ 31.50M$ 93.06M$ 92.17M$ 5.75M$ 5.75M
Diluted Average Shares
$ 51.50M$ 93.06M$ 92.17M$ 16.93M$ 20.00M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 644.37K$ 120.29M$ 598.89M$ 549.18K$ 3.64K
Net Income From Continuing And Discontinued Operation
$ 8.85M$ -21.17M$ -106.00M$ -545.73K$ -3.64K
Normalized Income
$ 3.33M$ 5.72M$ -106.00M$ -1.05M$ -3.64K
Interest Expense
--$ 2.72M--
EBIT
$ -644.37K$ -16.52M$ -98.35M$ -549.18K$ -3.64K
EBITDA
$ -644.37K$ -11.18M$ -67.20M$ -549.18K$ -3.64K
Currency in USD

LakeShore Biopharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis